Amongst those biomarkers, NRG1 exhibits higher expression in the amygdala and hippocampus brain subregions and was suggested as a non-invasive liquid-biopsy biomarker for the diagnosis of MDD patients. This evidence concerns the gene NRG1 and major depressive disorder.